Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

RTRahul ThakurTOTracey L. O’ConnorFKFrank Kuhr

Discussion

Loading...

Member takes

Overview

Prospective study shows CMMC detection accurately aligns with bone marrow MRD in multiple myeloma patients, suggesting improvements in patient monitoring and treatment strategies.

Key Points

  • Assess the correlation of circulating multiple myeloma cells (CMMCs) with minimal residual disease (MRD) in multiple myeloma patients.
  • Prospective study involving 51 multiple myeloma patients undergoing CAR T or autologous stem cell transplant.
  • Peripheral blood and bone marrow samples collected; MRD assessed via next-generation sequencing (ClonoSEQ).
  • CMMCs isolated and enumerated using CELLSEARCH platform and anti-CD138 ferrofluid.
  • CMMC positivity (>2 cells/4 mL) found in 55% of patients; 89.3% sensitivity and 91.3% specificity for detecting MRD. 90.2% concordance with bone marrow MRD confirmed via Cohen's kappa of 0.79.
  • Strong correlation (ρ = 0.72) between CMMC counts and quantitative MRD levels in bone marrow.

Cite This Study

Thakur et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da97https://doi.org/10.1182/blood-2025-4075
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma2025 · 1 citations
  2. 2Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients2024 · 7 citations
  3. 3Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  4. 4Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 1 citations
  5. 5Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells2025 · 1 citations